等待開盤 09-20 09:30:00 美东时间
0.000
0.00%
Oppenheimer has initiated coverage of Vaxart (NASDAQ:VXRT) with an outperform rating, citing the company’s focus on oral vaccines. The investment bank said it's optimistic about Vaxart’s (VXRT) differ...
08-16 03:53
HC Wainwright & Co. analyst Matthew Caufield reiterates HilleVax (NASDAQ:HLVX) with a Neutral and maintains $2 price target.
08-12 20:14
HilleVax (NASDAQ:HLVX) reported quarterly losses of $(0.83) per share which missed the analyst consensus estimate of $(0.43) by 93.02 percent. This is a 12.16 percent decrease over losses of $(0.74) per share from the
08-09 13:57
Cooling inflation sparked a jump in small-cap stocks in July, leaving their key index with its best performance in eight months. The Russell 2000 (RTY) climbed 10.4% in July, and drew the iShares Rus...
08-01 06:37
HilleVax, Inc (HLVX) has provided an announcement. HilleVax, Inc. has successfu...
07-24 05:18
HilleVax's (NYSE:HLVX) short percent of float has risen 14.66% since its last r...
07-10 04:45
Guggenheim analyst Seamus Fernandez downgrades HilleVax (NASDAQ:HLVX) from Buy to Neutral.
07-09 00:46
Shares of HilleVax fell after the release of Phase 2b trial results for HIL-214, a vaccine for norovirus-related acute gastroenteritis in infants. The study showed 5% efficacy and no significant clinical benefits. Development in infants will be discontinued.
07-08 21:43
HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced topline data results from NEST-IN1. NEST-IN1 is a Phase 2b, randomized,
07-08 19:35